These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26171179)

  • 21. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.
    Perrone V; Saragoni S; Buda S; Broccoli A; Degli Esposti L
    Biologics; 2016; 10():157-165. PubMed ID: 27942203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
.
    London G; Mann J; Goldsmith D; Combe C; Dellanna F; Zaoui P; Hoebel N; Krendyukov A; MacDonald K; Abraham I
    Clin Nephrol; 2018 Jan; 89 (2018)(1):1-9. PubMed ID: 29168688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
    Covic A; Abraham I
    Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.
    Osterborg A; Brandberg Y; Molostova V; Iosava G; Abdulkadyrov K; Hedenus M; Messinger D;
    J Clin Oncol; 2002 May; 20(10):2486-94. PubMed ID: 12011126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D; George MJ; Harrison LB
    Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study.
    Stoppa G; D'Amore C; Conforti A; Traversa G; Venegoni M; Taglialatela M; Leone R;
    BioDrugs; 2018 Aug; 32(4):367-375. PubMed ID: 30030767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
    Abdelrazik N; Fouda M
    Hematology; 2007 Dec; 12(6):533-41. PubMed ID: 17852440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
    Castelli R; Deliliers GL; Colombo R; Moreo G; Gallipoli P; Pantaleo G
    Ann Hematol; 2014 Sep; 93(9):1523-9. PubMed ID: 24711171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients.
    Mantovani G; Ghiani M; Curreli L; Maccio A; Massa D; Succu G; Lai P; Massa E; Mudu MC; Astara G
    Oncol Rep; 1999; 6(2):421-6. PubMed ID: 10023014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.
    Hudis CA; Vogel CL; Gralow JR; Williams D;
    Clin Breast Cancer; 2005 Jun; 6(2):132-42. PubMed ID: 16001991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors.
    Alifieris CE; Orfanakos K; Papanota A; Stathopoulos GP; Sitaras N; Trafalis DT
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):717-725. PubMed ID: 28078434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
    Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
    Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
    Provenzano R; Garcia-Mayol L; Suchinda P; Von Hartitzsch B; Woollen SB; Zabaneh R; Fink JC;
    Clin Nephrol; 2004 Jun; 61(6):392-405. PubMed ID: 15224803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilar Retacrit
    Losem C; Koenigsmann M; Rudolph C
    Onco Targets Ther; 2017; 10():1295-1305. PubMed ID: 28280364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.